The sequestration of uranium, particularly
from the deposited bones,
has been an incomplete task in chelation therapy for actinide decorporation.
Part of the reason is that all previous decorporation ligands are
not delicately designed to meet the coordination requirement of uranyl
cations. Herein, guided by DFT calculation, we elaborately design
a hexadentate ligand (TAM-2LI-MAM2), whose preorganized
planar oxo-donor configuration perfectly matches the typical coordination
geometry of the uranyl cation. This leads to an ultrahigh binding
affinity to uranyl supported by an in vitro desorption
experiment of uranyl phosphate. Administration of this ligand by prompt
intraperitoneal injection demonstrates its uranyl removal efficiencies
from the kidneys and bones are up to 95.4% and 81.2%, respectively,
which notably exceeds all the tested chelating agents as well as the
clinical drug ZnNa3-DTPA, setting a new record in uranyl
decorporation efficacy.